Peter Olagunju

Peter Olagunju

FerGene

Peter Olagunju is a Cell & Gene Therapy executive currently serving as senior vice president of technical operations at FerGene where he oversees manufacturing, process and analytical development, quality and supply chain for the company.

Prior to joining the company Peter served as the vice president of patient operations with bluebird bio, a biotech company in Cambridge. In this role, Peter had responsibility for the personalized manufacturing & Centers of Excellence (COE) engagement activities including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments. During his tenure at bluebird bio, Peter also served as the program leader for Zynteglo®, which was approved by the European Medicines Agency (EMA) for patients with transfusion dependent thalassemia. As program lead, he was responsible for the program development team, which was comprised of cross functional representatives spanning research, development, and commercial.

Find out why we're the best partner to help you find your next executive hire.